Bone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer

This secondary analysis of a randomized clinical trial among patients with metastatic, hormone-sensitive prostate cancer examines the association of bone pain at diagnosis with overall and progression-free survival.


Introduction
Overall survival (OS) among patients with metastatic, hormone-sensitive prostate cancer (MHSPC) receiving androgen deprivation therapy (ADT) intensification has significantly improved, reaching a median of 81.1 months. 1 The currently recommended therapy for MHSPC is ADT with androgen receptor pathway inhibitors with or without docetaxel. 2Establishing baseline biomarkers that can reliably predict survival outcomes could facilitate more personalized treatment approaches.For instance, bone metastases contribute to a decline in quality of life through the induction of skeletalrelated events and pain, impacting patients' physical, emotional, and functional well-being. 3Multiple studies have consistently demonstrated that the presence of cancer-related bone pain in individuals with metastatic, castration-resistant prostate cancer (MCRPC) is associated with poorer prognosis. 4,5wever, in the context of MHSPC, there are limited data on the effects of bone pain on survival outcomes.Hence, we sought to investigate the association between bone pain at MHSPC diagnosis and survival outcomes using patient-level data from the SWOG-1216 phase 3 randomized clinical trial.

Methods
In the primary SWOG-1216 trial (NCT01809691), a multicenter trial funded by the National Cancer Institute (NCI) and conducted from March 1, 2013, to July 15, 2017, patients from 248 academic and community centers across the US with newly diagnosed MHSPC were randomized in a 1:1 ratio to receive either ADT with orteronel, 300 mg orally twice daily, in the experimental arm or ADT with bicalutamide, 50 mg orally daily, in the control arm until disease progression, unacceptable toxic effects, or patient withdrawal (the trial protocol is in Supplement 1).The primary outcome was OS.
The methods and primary findings of the trial were detailed in a prior publication. 1The trial was approved by the NCI's central institutional review board and complied with international Good Clinical Practice and the Declaration of Helsinki, 6 with all participants giving written consent.This post hoc secondary analysis of the SWOG-1216 trial was conducted from September 1 to December 31, 2023.The current study adhered to the reporting guidelines outlined in the Consolidated

Standards of Reporting Trials (CONSORT).
All patients in the intention-to-treat population of the original trial who had available bone pain status were eligible for this secondary analysis (eFigure in Supplement 2).In this secondary analysis, baseline bone pain was categorized based on the presence or absence of bone pain.The presence of bone pain (yes or no) was collected before registration (ie, at baseline and per the treating physician's clinical assessment).Overall survival, defined as the time from randomization to death from any cause, was the primary end point.Key secondary end points were progression-free survival (PFS), defined as the time from randomization to biochemical, radiographic, or clinical progression (per

JAMA Network Open | Oncology
Bone Pain and Survival Outcomes for Metastatic, Hormone-Sensitive Prostate Cancer Prostate Cancer Working Group 2 criteria) or death from any cause, and prostate-specific antigen (PSA) response.The PSA response rates were categorized at a 7-month landmark after random assignment into complete response (<0.2 ng/mL), partial response (0.2-4.0 ng/mL), and no response (>4.0 ng/mL) (to convert to μg/L, multiply by 1.0).

Statistical Analysis
Baseline characteristics were summarized using medians and interquartile ranges (IQRs) for nonnormally distributed continuous variables and counts and percentages for categorical variables.
Differences in baseline characteristics by bone pain status at MHSPC diagnosis were assessed with χ 2 tests for categorical variables and Wilcoxon tests for continuous variables.Survival outcomes, including median PFS and OS, were calculated using Kaplan-Meier curves.Cox proportional hazards regression models were used for both univariable and multivariable analyses adjusting for variables including age, treatment type, Gleason score, disease volume, Zubrod performance status (score range, 0-4, with higher scores indicating poorer performance status), and PSA level, which was log 2 transformed for normalization.Complete cases without any missing information were included in our multivariable model.We used a significance level of P <.05, and all hypotheses tested were 2-sided.R software, version 4.2.3 (R Project for Statistical Computing) was used for statistical analysis.

Results
Of the 1279 male patients in the intention-to-treat population, 301 (23.5%) experienced baseline bone pain at MHSPC diagnosis while 896 (70.1%) did not.Bone pain status was unavailable for 82 patients (6.4%).For the 1197 included patients with available bone pain status, the median age was

Discussion
In this post hoc secondary analysis of the SWOG-1216 randomized clinical trial, we found that patients presenting with bone pain at the time of MHSPC diagnosis and treated with ADT in combination with either bicalutamide or a novel androgen receptor pathway inhibitor (orteronel) had poorer OS and PFS than those without bone pain at diagnosis.Additionally, those with bone pain had more aggressive disease presentation and lower complete PSA response rates.In general, patientreported outcomes, including pain, significantly impact clinical outcomes in patients with cancer. 7In patients with MCRPC, cancer-related pain and the use of opioid analgesics have served as prognostic determinants for unfavorable clinical progression independently of the treatment received. 4,8milarly, pain has consistently been shown to be a factor associated with lower OS, notably in patients with MCRPC treated with abiraterone or enzalutamide. 9,10In the context of MHSPC, there are limited data from prospective trials regarding bone pain and survival outcomes.In the GETUG-15 trial investigating docetaxel with ADT, pain intensity was shown as one of the factors associated with reduced OS. 11possible biological rationale underlying the association between bone pain and prostate cancer survival outcomes may stem from the presence of growth factors within the prostate tumor, notably nerve growth factor (NGF).Nerve growth factor has the capacity to modulate inflammatory and neuropathic pain conditions. 12Furthermore, NGF can trigger the activation of tropomyosin receptor kinase A (TrkA), which could initiate the proliferation and progression of prostate tumor cells through the interaction between TrKa and the androgen receptor, a pivotal component in prostate cancer proliferation. 13Therefore, NGF could mediate both pain and tumor growth.

Limitations
The limitations of this secondary analysis of a prospective phase 3 trial include its post hoc nature.In addition, although orteronel significantly improved PFS, it did not improve OS and hence did not garner regulatory approval. 1Furthermore, the multivariable analysis in the current study did not account for synchronous vs metachronous disease status since this was not an established prognostic factor at the time when the original trial was conceptualized in 2011.However, bone pain was associated with poor outcomes regardless of the treatment arm in our current analysis and therefore may have implications in the management of MHSPC after external validation.

Conclusions
This post hoc analysis of the SWOG-1216 phase 3 randomized clinical trial found that patients with MHSPC with baseline bone pain had worse survival outcomes than those without baseline bone pain.
These results highlight the need to consider bone pain in prognostic modeling, treatment selection, patient monitoring, and follow-up and suggest prioritizing these patients for clinical trials and immediate systemic treatment initiation.

Table 2 .
Multivariable Analysis of PFS and OS Dashed lines indicate the median time participants experienced OS or PFS; shading represents 95% CIs.
Abbreviations: AHR, adjusted hazard ratio; NA, not applicable; OS, overall survival; PFS, progression-free survival; PSA, prostate-specific antigen.aAdjusted for age, treatment type, Gleason score, disease volume, Zubrod performance status, and log 2 -transformed PSA level.bDefined as greater than minimal involvement of vertebrae, pelvic bones, and/or lymph nodes.Low-volume disease was the reference category.cPossible score range, 0-4, with higher scores indicating poorer performance status.Figure.Kaplan-Meier Estimates of Overall Survival (OS) and Progression-Free Survival (PFS) by Bone Pain in the Overall Population